^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Keytruda (pembrolizumab)

    i
    Company:
    Merck (MSD)
    Drug class:
    PD1 inhibitor
    Related drugs:
    Apply
    Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients (NeoCARD) (NCT06845319)
    Phase 2
    Medical University of South Carolina
    Not yet recruiting
    Last update posted :
    02/25/2025
    Initiation :
    06/01/2025
    Primary completion :
    06/30/2027
    Completion :
    06/30/2028
    BRCA
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel
    A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004) (NCT06345729)
    Phase 3
    Merck Sharp & Dohme LLC
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    05/24/2024
    Primary completion :
    02/19/2029
    Completion :
    02/18/2031
    KRAS
    |
    Keytruda (pembrolizumab) • MK-1084
    Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations (SWOG S2001) (NCT04548752)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/22/2021
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    BRCA1 • BRCA
    |
    BRCA mutation
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • cisplatin • Pembroria (pembrolizumab biosimilar)
    TTI-622 in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT05507541)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/19/2023
    Primary completion :
    11/01/2026
    Completion :
    11/01/2027
    PD-L1 • ALK • BCL2 • BCL6 • IRF4
    |
    ALK positive
    |
    Keytruda (pembrolizumab) • maplirpacept (TTI-622) • ontorpacept (PF-07901800)
    Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) (NCT06041503)
    Phase 2
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/27/2025
    Primary completion :
    10/01/2027
    Completion :
    10/01/2028
    CD4
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)
    Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer. (ACCESS-I) (NCT06670911)
    Phase 2
    Instituto Nacional de Cancer, Brazil
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/20/2025
    Primary completion :
    04/01/2026
    Completion :
    04/01/2028
    PD-L1
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel
    Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial (ACCIO) (NCT04267848)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/16/2020
    Primary completion :
    12/15/2025
    Completion :
    12/15/2025
    EGFR • PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • Pembroria (pembrolizumab biosimilar) • liposomal gemcitabine (FF-10832)
    Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial (ACHIEVE Study) (NCT06096844)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    07/19/2024
    Primary completion :
    06/01/2026
    Completion :
    06/01/2026
    EGFR • PD-L1 • ALK
    |
    ALK translocation • EGFR negative
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
    Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery (SWOG 1512) (NCT02775851)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/06/2017
    Primary completion :
    04/14/2023
    Completion :
    05/15/2026
    TMB • CD8 • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
    DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (KEYNOTE-797) (NCT04042701)
    Phase 1
    Daiichi Sankyo
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/10/2020
    Primary completion :
    07/01/2025
    Completion :
    08/01/2025
    EGFR • HER-2 • BRAF • ALK • ROS1
    |
    HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion
    |
    Keytruda (pembrolizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia (NCT04712851)
    Phase 2
    Jonsson Comprehensive Cancer Center
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/30/2021
    Primary completion :
    01/31/2026
    Completion :
    01/31/2027
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)
    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 (NCT04613596)
    Phase 2/3
    Mirati Therapeutics Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    12/02/2020
    Primary completion :
    10/31/2028
    Completion :
    10/31/2029
    PD-L1 • KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Krazati (adagrasib)
    Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NCT02194738)
    Phase N/A
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/26/2014
    Primary completion :
    09/28/2026
    Completion :
    09/28/2026
    EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4
    |
    EGFR mutation • ALK rearrangement
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • cisplatin • Xalkori (crizotinib) • erlotinib • carboplatin • gemcitabine • paclitaxel • docetaxel • Mektovi (binimetinib) • pemetrexed • sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed) • liposomal gemcitabine (FF-10832)
    A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC (ARTEMIDE-Lung03) (NCT06627647)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/27/2024
    Primary completion :
    05/10/2029
    Completion :
    03/25/2030
    PD-L1
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • rilvegostomig (AZD2936)
    A Study of SGN-PDL1V in Advanced Solid Tumors (SGNPDL1V-001) (NCT05208762)
    Phase 1
    Seagen Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    10/25/2022
    Primary completion :
    11/18/2027
    Completion :
    11/17/2028
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • PF-08046054
    Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) (NCT03829319)
    Phase 3
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    02/21/2025
    Initiation :
    03/25/2019
    Primary completion :
    08/11/2023
    Completion :
    08/30/2024
    EGFR • ALK • ROS1
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Lenvima (lenvatinib) • pemetrexed
    Reinvigorating TNBC Response to Immunotherapy with Combination Myeloid Inhibition and Radiation (NCT05491226)
    Phase 2
    Stephen Shiao
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/17/2023
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    HER-2 • PD-L1
    |
    Keytruda (pembrolizumab) • Niktimvo (axatilimab-csfr)
    Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma (NCT05155033)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/18/2022
    Primary completion :
    09/01/2026
    Completion :
    09/01/2027
    PD-L1
    |
    Keytruda (pembrolizumab) • Proleukin (aldesleukin)
    Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors (NCT05887492)
    Phase 1/2
    Tango Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    06/12/2023
    Primary completion :
    01/01/2026
    Completion :
    06/01/2026
    STK11
    |
    STK11 mutation
    |
    Keytruda (pembrolizumab) • TNG260
    Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D) (MK-3475-016) (NCT04098068)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Completed
    Last update posted :
    02/20/2025
    Initiation :
    01/25/2018
    Primary completion :
    05/15/2022
    Completion :
    02/05/2025
    TMB
    |
    Keytruda (pembrolizumab)
    A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 (KEYNOTE-D78) (NCT04879329)
    Phase 2
    Seagen Inc.
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    05/03/2022
    Primary completion :
    11/30/2026
    Completion :
    05/30/2028
    HER-2
    |
    HER-2 expression
    |
    Keytruda (pembrolizumab) • Aidixi (disitamab vedotin)
    Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients (HARMONi-3) (NCT05899608)
    Phase 3
    Summit Therapeutics
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    10/26/2023
    Primary completion :
    12/31/2027
    Completion :
    12/31/2028
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Yidafan (ivonescimab)
    A Study of SGN-B6A in Advanced Solid Tumors (SGNB6A-001) (NCT04389632)
    Phase 1
    Seagen Inc.
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    06/08/2020
    Primary completion :
    11/30/2026
    Completion :
    02/28/2028
    HER-2
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • sigvotatug vedotin (PF-08046047)
    Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma (POLESTAR) (NCT05268510)
    Phase 2
    Institut für Klinische Krebsforschung IKF GmbH ...
    Completed
    Last update posted :
    02/20/2025
    Initiation :
    09/15/2022
    Primary completion :
    08/27/2024
    Completion :
    01/09/2025
    HER-2 • PD-L1 • CD8 • CD4
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • capecitabine • oxaliplatin
    A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) (NCT05920356)
    Phase 3
    Amgen
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    11/16/2023
    Primary completion :
    06/30/2026
    Completion :
    06/30/2031
    PD-L1 • KRAS
    |
    PD-L1 expression • PD-L1 negative
    |
    Keytruda (pembrolizumab) • carboplatin • Lumakras (sotorasib)
    Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer (NCT04990921)
    Phase 2
    University of Louisville
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    09/02/2021
    Primary completion :
    07/01/2031
    Completion :
    07/01/2031
    HER-2 • ER
    |
    HER-2 overexpression
    |
    Keytruda (pembrolizumab)
    Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 (KEYNOTE-D74) (NCT05911295)
    Phase 3
    Seagen Inc.
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    09/22/2023
    Primary completion :
    06/30/2026
    Completion :
    04/30/2029
    HER-2
    |
    HER-2 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • Aidixi (disitamab vedotin)
    Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC (NCT04093167)
    Phase 2/3
    Canadian Cancer Trials Group
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    05/26/2020
    Primary completion :
    12/31/2026
    Completion :
    07/30/2027
    EGFR • PD-L1 • ALK
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)
    Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes (KELLY) (NCT03222856)
    Phase 2
    MedSIR
    Completed
    Last update posted :
    02/19/2025
    Initiation :
    12/14/2017
    Primary completion :
    10/31/2018
    Completion :
    12/23/2020
    HER-2 • PD-L1 • ER • PGR • TMB
    |
    PD-L1 expression • HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Keytruda (pembrolizumab) • Halaven (eribulin mesylate)
    A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (NCT05852691)
    Phase 2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    07/18/2023
    Primary completion :
    12/24/2026
    Completion :
    12/24/2026
    HER-2 • PD-L1 • ER • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • albumin-bound paclitaxel • tobemstomig (RG6139)
    LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC (NCT06216301)
    Phase 3
    NovoCure GmbH
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    07/31/2024
    Primary completion :
    10/01/2028
    Completion :
    10/01/2028
    PD-L1
    |
    Keytruda (pembrolizumab)
    Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative (NCT04929041)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    10/07/2022
    Primary completion :
    12/31/2027
    Completion :
    12/31/2027
    EGFR • PD-L1 • ALK • ROS1
    |
    PD-L1 expression • ALK mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed • ABP 206 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed)
    A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% (RELATIVITY-1093) (NCT06561386)
    Phase 3
    Bristol-Myers Squibb
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    10/07/2024
    Primary completion :
    07/30/2030
    Completion :
    11/11/2033
    PD-L1
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • carboplatin • pemetrexed • Opdualag (nivolumab/relatlimab-rmbw)
    Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer (NCT02907099)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    02/19/2025
    Initiation :
    12/01/2016
    Primary completion :
    10/06/2023
    Completion :
    10/06/2023
    PD-L1
    |
    Keytruda (pembrolizumab) • Aphexda (motixafortide)
    Converting HR+ Breast Cancer Into an Individualized Vaccine (NCT03804944)
    Phase 2
    Weill Medical College of Cornell University
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    03/17/2020
    Primary completion :
    12/01/2025
    Completion :
    12/01/2027
    HER-2 • PGR
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Mobista (CDX-301)
    Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) (NCT04526691)
    Phase 1
    Daiichi Sankyo
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    09/15/2020
    Primary completion :
    04/15/2026
    Completion :
    04/15/2026
    EGFR • KRAS • BRAF • ALK • ROS1 • PD-L2 • NTRK • TACSTD2
    |
    KRAS mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Datroway (datopotamab deruxtecan)
    P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT03113487)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    02/01/2018
    Primary completion :
    08/26/2022
    Completion :
    06/03/2025
    PD-L1 • TP53 • MUC16
    |
    TP53 mutation
    |
    Keytruda (pembrolizumab) • p53MVA
    Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %. (IMMUNOMEK) (NCT05937906)
    Phase 1/2
    Centre Georges Francois Leclerc
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    07/30/2024
    Primary completion :
    05/25/2028
    Completion :
    05/25/2028
    PD-L1
    |
    Keytruda (pembrolizumab) • carboplatin • Gomekli (mirdametinib)
    Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy (NCT06439836)
    Phase 1
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    02/18/2025
    Initiation :
    02/21/2025
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    PD-L1 • CD68 • CRP
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • emavusertib (CA-4948)
    Pembrolizumab in Combination with Plinabulin and Docetaxel for Metastatic NSCLC After ICIs (KeyPemls-004) (NCT05599789)
    Phase 2
    Peking Union Medical College Hospital
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    02/01/2023
    Primary completion :
    01/21/2025
    Completion :
    12/31/2025
    EGFR • ALK • ROS1
    |
    Keytruda (pembrolizumab) • docetaxel • plinabulin (BPI 2358)